Repatha OK'd; Payers Eye PCSK9 Rebate/Discount War
This article was originally published in Scrip
Seeking to stay ahead of the other proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor on the US market, Amgen said it was pricing its newly approved drug Repatha (evolocumab) at $14,100 per year – $500 below Sanofi's and Regeneron Pharmaceuticals' Praluent (alirocumab), whose annual cost is $14,600.
You may also be interested in...
The battle for PCSK9 inhibitor market share continues with Amgen’s Repatha outselling Praluent, but a now-ended patent dispute no longer threatens Regeneron’s ability to sell its product in the US.
Amgen and Novartis won the first US FDA approval for a CGRP inhibitor in the prevention of migraine headaches. The companies aim to quickly capture a big share of what they estimate to be an 8m-patient market in the US with a $6,900 per year price tag.
Three and a half months after Ionis Pharmaceuticals Inc. surprised investors with the news that Sanofi's Genzyme business unit would no longer market Kynamro (mipomersen) for homozygous familial hypercholesterolemia (HoFH), the Carlsbad, California-based biotechnology company revealed that it sold global rights to the cholesterol-lowering drug to Kastle Therapeutics LLC for up to $95m.